drugset / Trial / NCT07552324
Study on the Treatment of Double/Triple-hit DLBCL With Chidamide and Lisaftoclax in Combination With Pola-R-CHP
NaSingle-groupOpen-labelTreatment
Summary
This is an open-label, multicenter clinical study for patients aged 65 and above with double/triple-hit diffuse large B-cell lymphoma who are not suitable for transplantation. The study employs a 6-cycle CL-Pola-R-CHP regimen, with cycles repeated every 21 days.
Timeline
- Start
- 2026-05-01
- Primary completion
- 2027-05-31
- Completion
- 2028-05-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | APG-2575 | Small molecule | 600 mg | — |
| Subject | Cyclophosphamide | Other / unclassified | 750 mg/m2 | — |
| Subject | Doxorubicin | Other / unclassified | 50 mg/m2 | — |
| Subject | Pola | Unknown | 1.8 mg/kg | — |
| Subject | Prednisone | Other / unclassified | 60 mg/m2 | — |
| Subject | Rituximab | Monoclonal antibody | 375 mg/m2 | — |
| Subject | Tucidinostat | Small molecule | 20 mg | — |